Skip to content
Beraprost
Beraprost is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target prostaglandin E2 receptor EP4 subtype, prostacyclin receptor, and prostaglandin E2 receptor EP3 subtype.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AC: Platelet aggregation inhibitors excl. heparin
— B01AC19: Beraprost
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic renal insufficiencyD051436N18—1—1—2
Type 2 diabetes mellitusD003924EFO_0001360E11———1—1
Pulmonary hypertensionD006976EFO_0001361I27.20———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pulmonary arterial hypertensionD000081029—42——6
Chronic kidney failureD007676EFO_0003884N18.6—11——1
NephrosclerosisD009400EFO_1000041I12—11——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal insufficiencyD051437HP_0000083N191————1
Healthy volunteers/patients—1————1
Essential hypertensionD000075222I101————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Arteriovenous fistulaD001164Q27.3————11
Diabetic nephropathiesD003928EFO_0000401————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBERAPROST
INNberaprost
Description
Beraprost is an organic heterotricyclic compound that is (3aS,8bS)-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan in which the hydrogens at positions 1R, 2R and 5 are replaced by (3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl, hydroxy and 3-carboxypropyl groups, respectively. It is a prostaglandin receptor agonist which is approved to treat pulmonary arterial hypertension in Asia. It has a role as a vasodilator agent, a platelet aggregation inhibitor, an antihypertensive agent, a prostaglandin receptor agonist and an anti-inflammatory agent. It is a monocarboxylic acid, an organic heterotricyclic compound, a secondary alcohol, a secondary allylic alcohol and an enyne. It is a conjugate acid of a beraprost(1-).
Classification
Small molecule
Drug classprostaglandins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2c3cccc(CCCC(=O)O)c3O[C@H]2C[C@H]1O
Identifiers
PDB—
CAS-ID88430-50-6
RxCUI—
ChEMBL IDCHEMBL1207745
ChEBI ID—
PubChem CID6917951
DrugBankDB05229
UNII ID35E3NJJ4O6 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
PTGER4
PTGER4
PTGIR
PTGIR
PTGER3
PTGER3
Organism
Homo sapiens
Gene name
PTGER4
Gene synonyms
PTGER2
NCBI Gene ID
5734
Protein name
prostaglandin E2 receptor EP4 subtype
Protein synonyms
PGE receptor, EP4 subtype, PGE2 receptor EP4 subtype, prostaglandin E receptor 4 (subtype EP4), Prostanoid EP4 receptor
Uniprot ID
Q3MJ87
Mouse ortholog
Ptger4 (19219)
prostaglandin E2 receptor EP4 subtype (P32240)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,203 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
304 adverse events reported
View more details